Europe Human Papilloma Virus/HPV Test and Pap Smear/Test Market (2025-2030)
The Europe Human Papilloma Virus/HPV Test and Pap Smear/Test Market was valued at $506.7 Million in 2025 and projected to reach to $871.9 Million by 2030, representing a compound annual growth rate of 11.5%. Europe's HPV Test and Pap Smear market is poised for sustained expansion driven by increasing cervical cancer screening awareness and the transition from conventional Pap smears to more sensitive HPV-based testing methodologies.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Europe Human Papilloma Virus/HPV Test and Pap Smear/Test Market Trends and Insights
- Europe's market growth is driven by increasing cervical cancer screening awareness, robust healthcare infrastructure, and widespread adoption of HPV-based testing protocols across member states.
- The region benefits from established reimbursement frameworks and regulatory support for preventive oncology diagnostics. In Europe, the shift from traditional Pap smear testing toward HPV co-testing and primary HPV screening reflects evolving clinical guidelines and improved diagnostic accuracy.
- Europe's aging population and emphasis on early disease detection further accelerate market expansion between 2025 and 2030.
- Strong government initiatives promoting cervical cancer prevention across Europe underscore the region's commitment to reducing disease burden through accessible screening programs..
Key Market Statistics
- CAGR (2025-2030) 11.5% CAGR
- Market Size, 2025 ~USD 506.7 Million
- Forecast, 2030 ~USD 871.9 Million
- Geography Europe
Europe Human Papilloma Virus/HPV Test and Pap Smear/Test Market Overview
Market Valuation & Growth :
Europe's HPV Test and Pap Smear market is valued at USD 506.7 million in 2025, with a robust CAGR of 11.5% projected through 2030, reaching USD 871.9 million. This growth significantly outpaces the global CAGR of 10%, positioning Europe as a high-growth region.
Healthcare Infrastructure Advantage :
Europe benefits from well-established healthcare systems and universal screening programs across member states. Strong regulatory frameworks and reimbursement policies support widespread adoption of advanced HPV-based testing protocols and cervical cancer prevention initiatives.
Screening Awareness & Prevention Focus :
Increasing cervical cancer screening awareness campaigns and government-backed prevention programs drive market expansion. European nations prioritize early detection through organized screening initiatives, supporting higher adoption rates of HPV testing over traditional Pap smear methods.
Regional Market Leadership :
Germany leads European adoption with USD 291 million market size, followed by the UK (USD 222.17 million) and France (USD 157.9 million). These markets demonstrate strong healthcare investment and advanced diagnostic infrastructure supporting HPV test proliferation.
Europe Human Papilloma Virus/HPV Test and Pap Smear/Test Market Dynamics
- Robust healthcare infrastructure, favorable reimbursement policies, and government-mandated screening programs across European nations create a conducive environment for market growth.
- The region's emphasis on preventive healthcare and early cancer detection supports continued adoption of advanced diagnostic technologies. Key growth catalysts include rising healthcare expenditure, integration of HPV testing into national screening guidelines, and technological advancements in molecular diagnostics.
- European countries' commitment to cervical cancer elimination through vaccination and screening programs further accelerates market penetration.
- With Germany, UK, and France leading adoption, the market is expected to reach USD 871.9 million by 2030, reflecting strong demand for improved diagnostic accuracy and patient outcomes across the region..
Related Ecosystem
In Vitro Diagnostics
- Polymerase Chain Reaction (PCR)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Dna Microarrays
- Assay Kits
- Microarrays
- ROCHE HOLDINGS AG
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Abbott Laboratories
- Biomerieux s.a.
Medical Devices
- Polymerase Chain Reaction (PCR)
- Magnetic Resonance Imaging (MRI)
- Disposable Autoinjectors
- Pulse Oximeters
- Blood Pressure Monitors
- Medtronic plc
- Abbott Laboratories
- Stryker Corporation
- Becton, Dickinson and Company
- CONMED Corporation
Key Takeaways
- Europe's HPV Test and Pap Smear Market is valued at USD 506.7 million in 2025 and will reach USD 871.9 million by 2030, growing at 11.5% CAGR.
- Europe is transitioning from Pap smear-only protocols to HPV primary screening and co-testing, driven by clinical evidence and regulatory endorsement.
- Established reimbursement systems and government-backed cervical cancer prevention programs across Europe support sustained market growth.
- Europe's aging female population and emphasis on preventive healthcare create strong demand for advanced HPV diagnostic solutions through 2030.
Human Papilloma Virus/HPV Test and Pap Smear/Test Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | VAGINAL CANCER SCREENING (Application) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 10% from 2025 to 2030 |
| Largest Segment | CERVICAL CANCER SCREENING (Application) |
| Market Size Base Year (Billions) | ~USD 2.45 (2025) |
| Revenue Forecast (Billions) | ~USD 3.94 (2030) |
| Segments Covered | Product & Service, Test Type, Type, Technology, Application, Care Setting |
Europe Human Papilloma Virus/HPV Test and Pap Smear/Test Market Report Segmentation
6 segment dimensions are covered across the global market.
By Product & Service
- Consumables
- Instruments
- Services
By Test Type
- Hpv Testing
- Pap Tests
By Type
- Co-Testing
- Follow-Up Hpv Testing
- Primary Hpv Testing
By Technology
- Cytology
- Immunodiagnostics
- Molecular Diagnostics
By Application
- Cervical Cancer Screening
- Vaginal Cancer Screening
By Care Setting
- Diagnostic Laboratories
- Hospitals
- Physicians’ Offices & Clinics
REST OF EUROPE: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| CERVICAL CANCER SCREENING | 172.7 | 182.4 | 195 | 210.5 | 229.7 | 253.3 | 281.6 | 316.8 | 10.2 |
| VAGINAL CANCER SCREENING | 13.4 | 14.4 | 15.7 | 17.2 | 19 | 21.3 | 24.1 | 27.6 | 12 |
| TOTAL | 186.1 | 196.9 | 210.7 | 227.6 | 248.7 | 274.7 | 305.7 | 344.4 | 10.3 |
EUROPE: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| CERVICAL CANCER SCREENING | 604.9 | 641.5 | 687.4 | 744 | 814.4 | 900.7 | 1004.3 | 1133.9 | 10.5 |
| VAGINAL CANCER SCREENING | 69.8 | 75.3 | 82.1 | 90.4 | 100.7 | 113.3 | 128.6 | 147.8 | 12.5 |
| TOTAL | 674.8 | 716.8 | 769.5 | 834.4 | 915 | 1014 | 1132.9 | 1281.7 | 10.7 |
Target Audience
- Diagnostic Device Manufacturers : Manufacturers of HPV testing kits and Pap smear equipment need detailed European market data to identify expansion opportunities, assess regional demand, and develop localized product strategies aligned with European healthcare standards and screening protocols.
- Healthcare Providers & Laboratories : Hospitals, diagnostic laboratories, and clinical centers require market insights to optimize service offerings, invest in HPV testing infrastructure, and align screening programs with regional guidelines and reimbursement models across European markets.
- Pharmaceutical & Biotech Companies : Companies developing HPV-related therapeutics and preventive solutions need comprehensive market intelligence to understand screening adoption rates, identify partnership opportunities, and align product development with European healthcare priorities.
- Healthcare Investors & Consultants : Investment firms and management consultants require detailed market forecasts and regional analysis to evaluate investment opportunities, assess market attractiveness, and guide strategic decisions in Europe's growing diagnostic testing sector.
- Government & Health Policy Organizations : Public health agencies and policy makers need market data to inform cervical cancer prevention strategies, optimize screening program budgets, and evaluate the economic impact of HPV testing adoption across European healthcare systems.
Key Companies in the Europe Human Papilloma Virus/HPV Test and Pap Smear/Test Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| BIOMERIEUX S.A. | France | Public Company | Microbiology & AST (VITEK 2, VITEK MS, VITEK REVEAL, API, ETEST, CHROMID, culture media),Molecular & Syndromic (BIOFIRE, SPOTFIRE, ARGENE, EMAG/NUCLISENS, BIOMERIEUX EPISEQ CS),Immunoassay & Sepsis (VIDAS, Hybiome CLIA), |
| INTERTEK GROUP PLC | United Kingdom | Public Company | Consumer Products,Corporate Assurance,Health and Safety, |
| QUIDEL CORPORATION | United States | Public Company | Labs (clinical chemistry and immunoassay),Transfusion Medicine,Point of Care, |
| HOLOGIC, INC. | United States | Private Company | Diagnostics (Aptima, Panther, ThinPrep, viral load, SARS-CoV-2),Breast Health (3D mammography, biopsy, localization, software),GYN Surgical (MyoSure, NovaSure, Fluent, Acessa, CoolSeal), |
| QIAGEN | Netherlands | Public Company | Sample technology consumables and instruments,Immune response and molecular diagnostics assays,PCR and digital PCR solutions, |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing and single-use solutions),Life Sciences (research tools and genomic medicines),Diagnostics (clinical instruments and consumables), |
| ABBOTT | United States | Public Company | Medical Devices,Diagnostic Products,Nutritional Products, |
| SEEGENE INC. | South Korea | Public Company | Respiratory infectious disease panels,Sexually transmitted infection and HPV assays,Gastrointestinal and meningitis syndromic panels, |
| SD BIOSENSOR, INC. | South Korea | Public Company | STANDARD Q rapid diagnostics,STANDARD F fluorescence immunodiagnostics,STANDARD E enzyme immunoassay, |
| SANSURE BIOTECH INC. | China | Public Company | Nucleic acid diagnostic reagents (respiratory, HPV, reproductive, blood-borne, GI, others),Rapid antigen tests,Nucleic acid extraction and purification kits, sample reagents, |
| MOLBIO DIAGNOSTICS LIMITED | India | Private Company | Truenat PCR platforms (instruments),Truenat assays and reagents,Disposable POCT devices (dengue, malaria, COVID-19, others), |
BIOMERIEUX S.A.
bioMérieux S.A. is a French public company founded in 1963 that employs 14,894 people. The company specializes in in vitro diagnostics and microbiology testing solutions.
INTERTEK GROUP PLC
Intertek Group PLC is a British public company established in 1885 with 45,425 employees. The company offers testing, inspection, and certification services across multiple industries.
QUIDEL CORPORATION
Quidel Corporation is a United States public company founded in 1979 with 6,500 employees. The company manufactures rapid diagnostic testing products and molecular assays.
HOLOGIC, INC.
Hologic, Inc. is a private United States company founded in 1985 with 7,070 employees. The company develops and manufactures diagnostic and medical imaging products.
QIAGEN
QIAGEN is a Dutch public company founded in 1984 with 5,500 employees. The company provides molecular diagnostics, sample preparation, and life sciences research tools.
DANAHER CORPORATION
Danaher Corporation is a United States public company founded in 1969 with 59,000 employees. The company operates across diagnostics, life sciences, and environmental solutions.
ABBOTT
Abbott is a United States public company founded in 1888 with 115,000 employees. The company is a diversified healthcare company providing diagnostics, medical devices, and pharmaceuticals.
SEEGENE INC.
Seegene Inc. is a South Korean public company founded in 2000 with 216 employees. The company specializes in molecular diagnostic testing and multiplex PCR technology.
SD BIOSENSOR, INC.
SD Biosensor, Inc. is a South Korean public company founded in 1999 with 576 employees. The company develops and manufactures rapid diagnostic test kits and point-of-care devices.
SANSURE BIOTECH INC.
Sansure Biotech Inc. is a Chinese public company founded in 2008 with 2,128 employees. The company develops molecular diagnostic reagents and testing solutions.
MOLBIO DIAGNOSTICS LIMITED
Molbio Diagnostics Limited is a private Indian company founded in 2000. The company develops and manufactures molecular diagnostic devices and testing solutions.
Countries within Europe - compare and drill down
| Country | 2025 size (native) |
|---|---|
| Germany | USD 291 Million |
| UK | USD 222.17 Million |
| France | USD 157.9 Million |
| Italy | USD 92.5 Million |
| Spain | USD 114.3 Million |
| Rest Of Europe | USD 283 Million |
Country market size visualization
Reasons to Buy this Report
- Regional Market Segmentation : Gain detailed insights into Europe's HPV and Pap smear market with country-level breakdowns including Germany, UK, France, Italy, and Spain. Understand regional variations in market size, growth rates, and adoption patterns to inform localized business strategies.
- Growth Opportunity Assessment : Identify high-growth segments within Europe's 11.5% CAGR market expansion. Evaluate emerging opportunities in underserved markets and assess competitive positioning across major European healthcare systems and diagnostic providers.
- Healthcare Policy Insights : Understand how European screening guidelines, reimbursement policies, and regulatory frameworks drive HPV test adoption. Leverage policy intelligence to navigate market entry strategies and align product offerings with regional healthcare priorities.
- Competitive Landscape Analysis : Benchmark against leading market players in Germany, UK, and France. Analyze competitive dynamics, market share distribution, and differentiation strategies among diagnostic manufacturers and healthcare providers across Europe.
- Forecast-Driven Planning : Utilize comprehensive 2025-2030 market forecasts to guide investment decisions, product development timelines, and market expansion plans. Make data-driven decisions based on projected market growth to USD 871.9 million by 2030.
Frequently asked questions
What is the market size of Europe's HPV Test and Pap Smear Market in 2025?
Europe's HPV Test and Pap Smear Market is valued at USD 506.7 million in 2025.
What is the projected market size for Europe by 2030?
Europe's market is projected to reach USD 871.9 million by 2030.
What is the CAGR for Europe's HPV Test and Pap Smear Market?
Europe's market is expected to grow at a compound annual growth rate (CAGR) of 11.5% from 2025 to 2030.
Why is Europe's HPV testing market growing faster than the global average?
Europe's 11.5% CAGR exceeds the global 10% CAGR due to strong healthcare infrastructure, established reimbursement systems, regulatory support for HPV screening, and government-backed cervical cancer prevention initiatives.
What is driving the shift from Pap smear to HPV testing in Europe?
Europe's transition is driven by clinical evidence supporting HPV primary screening superiority, updated regulatory guidelines, improved diagnostic accuracy, and healthcare system adoption of evidence-based preventive protocols.
RESEARCH METHODOLOGY
The study involved major activities in estimating the current market size for the global HPV testing and Pap test market.
Exhaustive secondary research was done to collect information on the HPV testing and Pap test market. The next step was to validate these findings, assumptions, and sizes with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the HPV testing and Pap test market.
Four steps involved in estimating the market size are as follows:
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for this study.
Primary Research
In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.
The following is a breakdown of the primary respondents:
Note 1: Others include sales, marketing, and product managers.
Note 2: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = > USD 100 million, tier 2 = USD 10 million to USD 100 million, and tier 3 = < USD 10 million
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both the top-down and bottom-up approaches were used to estimate and validate the HPV testing and Pap test market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size included the following:
- The key players in the industry have been identified through extensive secondary research.
- The revenues generated by leading players operating in the HPV testing and Pap test market have been determined through primary and secondary research.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
The research methodology used to estimate the market size included the following:
Data Triangulation
After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Human Papillomavirus (HPV) testing identifies the presence of high-risk HPV strains that can lead to cervical cancer and related abnormalities. It is increasingly adopted as a primary screening approach, either independently or alongside Pap testing (co-testing), to assess the risk of cervical disease.
The Papanicolaou (Pap) test is a cytological screening procedure used to detect precancerous and cancerous cells in the cervix, which connects the uterus and vagina. While primarily applied in cervical cancer screening, Pap tests can also detect abnormal or malignant cells in the vaginal canal in some cases.
Stakeholders
- Senior Management
- End Users
- Finance/Procurement Department
- R&D Department
Report Objectives
- To define, describe, segment, and forecast the global HPV testing and Pap test market by product & service, test type, technology, application, care setting, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall HPV testing and Pap test market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
- To benchmark players within the HPV testing and Pap test market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
- To study the impact of AI/Gen AI on the market, along with the macroeconomic outlook for each region
Get the Full Human Papilloma Virus/HPV Test and Pap Smear/Test Market Report
Full forecast, segment splits, and company analysis for all Human Papilloma Virus/HPV Test and Pap Smear/Test Market.
- US Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Canada Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Germany Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- UK Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- France Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Italy Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Spain Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- China Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Japan Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- India Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Brazil Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Mexico Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Saudi Arabia Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- UAE Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Rest Of Europe Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Rest Of Asia Pacific Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Rest Of Latam Human Papilloma Virus/HPV Test and Pap Smear/Test Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
